IMAPOLE
Acquired by
EURAZEO
IMAPOLE acquired by EURAZEO
Target
IMAPOLE
Acquirer
EURAZEO
Context
Eurazeo has partnered with Bpifrance to complete a major investment of over �50 million in Imap�le. The consortium is taking a minority stake alongside the founding associate radiologists.
IMAPOLE, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 12.8x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Based in Lyon, ImaOne is a prominent medical imaging group. The organization is managed and owned by a group of associate radiologists, providing essential diagnostic services to the regional healthcare ecosystem. As an independent player in the medical imaging sector, the group focuses on maintaining high standards of clinical excellence while navigating the evolving regulatory landscape for medical practices in France. Its operational model relies on the expertise of its medical associates to deliver specialized imaging services, ranging from standard diagnostics to advanced medical screenings.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with IMAPOLE
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.